Tremfya (guselkumab) is a Interleukin 23 antagonist indicated for the treatment of adult patients with:1 Moderate-to-severe plaque psoriasis who are candidates for systemic therapy or light therapy Active psoriatic arthritis (PsA) It is available as a single-dose syringe containing 100 mg guselkumab.1